Back to search results

PROGRESS Study: Improving Cancer Treatment with Genomic Information

This study, called PROGRESS, is looking at how we can better use genetic information from your tumor to guide cancer treatment. It focuses on patients with advanced solid tumors like breast, lung, colorectal, and bladder cancers. The study will use expert review of your tumor's genetic test results (next-generation sequencing or NGS) and a special navigator to help you and your doctors understand these results. The goal is to see if these interventions increase the use of treatments that are specifically chosen based on your tumor's genetic makeup (genome-informed therapy). You can join if you are 18 or older and have one of the specified cancers. The study is currently unclear on its recruitment status.

Study design
This is a single-arm study, meaning all participants receive the same interventions, and plans to enroll 500 people. It is an interventional study, but the phase is not specified.
What's involved
You will have blood or tissue samples collected for genetic testing as part of your standard care. A precision oncology navigator will help coordinate these tests and assist with financial aid if needed.
Compensation
Not stated in the trial record.
Follow-up
The study will measure the rate of genome-informed therapy orders at 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06896162

PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival

Recruiting
NAAges 18+InterventionalTreatment
UNC Lineberger Comprehensive Cancer Center
~500 participants
Updated 2026-07-14 on ClinicalTrials.gov
What's tested:Expert ReviewBlood or tissue samples collection.The Precision Oncology Navigation

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
The rate of genome informed therapy (GIT) orders
Measured over 2 years

Conditions

Solid Tumor Malignancies
Metastatic Cancer
Breast Cancer
Colorectal Cancer
Lung Cancer
Bladder Cancer

Explore related trials

Bladder CarcinomaBreast CarcinomaColorectal CarcinomaLung Non-Small Cell CarcinomaSolid Neoplasm

Where it's being run

1 sites across 1 states
North Carolina1

Study leadership

  • Carrie Lee · PRINCIPAL_INVESTIGATOR · UNC Lineberger Comprehensive Cancer Center

Who to contact

Stephanie Drotts
[email protected]
919-445-4872
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Written informed consent was obtained to participate in the study and HIPAA authorization for release of personal health information.
Subjects are willing and able to comply with study procedures based on the judgment of the investigator.
Age ≥ 18 years at the time of consent.
ECOG or Karnofsky Performance Status of 0-2.
Documented Stage IV solid tumor malignancy: NSCLC, CRC, Breast or Bladder Cancer
The treating provider deems Next Generation Sequencing (NGS) testing appropriate and plans to consider results in either first- or second-line therapy in the metastatic setting
A genomic tumor test has not been ordered or has been ordered but not resulted.

What this trial measures

  • The rate of genome informed therapy (GIT) orders2 years

    The rate of genome informed therapy (GIT) orders for Level 1/2 GIT will be compared against an estimated baseline historical GIT order.